Lead plaintiffs' attorney Jonathan Orent told USA TODAY that the warning letter "gives me tremendous comfort both that we're right, but also that the government is actually now doing something about these problems." He compared the reporting failures to "the opioid days," noting that expert witnesses reviewing the case had "not seen anything quite that bad." Novo Nordisk responded that the letter "does not make any conclusions about the quality or safety of our medicines" and that the company plans to "address the requests in the warning letter expeditiously and holistically." What This Means for GLP-1 Litigation Strengthening Failure-to-Warn Claims The warning letter provides plaintiffs' attorneys with a critical piece of evidence: documentation that Novo Nordisk had institutional procedures that systematically prevented adverse events from reaching the FDA
We validated radioprotection using WR-1065, the active form of Amifostine and tested other reported radioprotective drugs including Edaravone, Tempol, N-acetylcysteine, Rapamycin, Ex-Rad, and Palifermin
In studies of people with type 2 diabetes, Mounjaro was better than Ozempic at lowering HbA1C, with reductions of around 2.3% and supporting weight loss, with participants shedding 15.3% of body weight, depending on the dose
A registered dietitian can build a realistic, high-protein plan around your reduced appetite so youre protecting your body composition while still losing weight
2011;342:c7086
)
